Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 183

1.

Eculizumab in the treatment of atypical hemolytic uremic syndrome in infants.

Ariceta G, Arrizabalaga B, Aguirre M, Morteruel E, Lopez-Trascasa M.

Am J Kidney Dis. 2012 May;59(5):707-10. doi: 10.1053/j.ajkd.2011.11.027.

PMID:
22196848
2.

Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases.

Fakhouri F, Delmas Y, Provot F, Barbet C, Karras A, Makdassi R, Courivaud C, Rifard K, Servais A, Allard C, Besson V, Cousin M, Châtelet V, Goujon JM, Coindre JP, Laurent G, Loirat C, Frémeaux-Bacchi V.

Am J Kidney Dis. 2014 Jan;63(1):40-8. doi: 10.1053/j.ajkd.2013.07.011.

PMID:
24021908
3.

Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.

Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, Nürnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T, Loirat C.

N Engl J Med. 2013 Jun 6;368(23):2169-81. doi: 10.1056/NEJMoa1208981.

4.

Pulse cyclophosphamide therapy and clinical remission in atypical hemolytic uremic syndrome with anti-complement factor H autoantibodies.

Boyer O, Balzamo E, Charbit M, Biebuyck-Gougé N, Salomon R, Dragon-Durey MA, Frémeaux-Bacchi V, Niaudet P.

Am J Kidney Dis. 2010 May;55(5):923-7. doi: 10.1053/j.ajkd.2009.12.026.

PMID:
20202729
5.

Eculizumab in atypical hemolytic uremic syndrome: long-term clinical course and histological findings.

Tschumi S, Gugger M, Bucher BS, Riedl M, Simonetti GD.

Pediatr Nephrol. 2011 Nov;26(11):2085-8. doi: 10.1007/s00467-011-1989-4.

PMID:
21877169
6.

Postpartum thrombotic microangiopathy revealed as atypical hemolytic uremic syndrome successfully treated with eculizumab: a case report.

Kourouklaris A, Ioannou K, Athanasiou I, Panagidou A, Demetriou K, Zavros M.

J Med Case Rep. 2014 Sep 14;8:307. doi: 10.1186/1752-1947-8-307.

7.

Neonatal onset atypical hemolytic uremic syndrome successfully treated with eculizumab.

Besbas N, Gulhan B, Karpman D, Topaloglu R, Duzova A, Korkmaz E, Ozaltin F.

Pediatr Nephrol. 2013 Jan;28(1):155-8. doi: 10.1007/s00467-012-2296-4.

PMID:
22956028
8.

Eculizumab in acute recurrence of thrombotic microangiopathy after renal transplantation.

Hadaya K, Ferrari-Lacraz S, Fumeaux D, Boehlen F, Toso C, Moll S, Martin PY, Villard J.

Am J Transplant. 2011 Nov;11(11):2523-7. doi: 10.1111/j.1600-6143.2011.03696.x.

9.

Long-term eculizumab improves clinical outcomes in atypical hemolytic uremic syndrome.

Vilalta R, Lara E, Madrid A, Chocron S, Muñoz M, Casquero A, Nieto J.

Pediatr Nephrol. 2012 Dec;27(12):2323-6. doi: 10.1007/s00467-012-2276-8.

10.

Plasma resistant atypical hemolytic uremic syndrome associated with a CFH mutation treated with eculizumab: a case report.

Sevinc M, Basturk T, Sahutoglu T, Sakaci T, Koc Y, Ahbap E, Akgol C, Kara E, Brocklebank V, Goodship TH, Kavanagh D, Unsal A.

J Med Case Rep. 2015 Apr 29;9:92. doi: 10.1186/s13256-015-0575-y.

11.

Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome.

Cugno M, Gualtierotti R, Possenti I, Testa S, Tel F, Griffini S, Grovetti E, Tedeschi S, Salardi S, Cresseri D, Messa P, Ardissino G.

J Thromb Haemost. 2014 Sep;12(9):1440-8. doi: 10.1111/jth.12615.

12.

Adult-onset eculizumab-resistant hemolytic uremic syndrome associated with cobalamin C deficiency.

Cornec-Le Gall E, Delmas Y, De Parscau L, Doucet L, Ogier H, Benoist JF, Fremeaux-Bacchi V, Le Meur Y.

Am J Kidney Dis. 2014 Jan;63(1):119-23. doi: 10.1053/j.ajkd.2013.08.031.

PMID:
24210589
13.

Eculizumab for atypical hemolytic uremic syndrome in pregnancy.

Ardissino G, Wally Ossola M, Baffero GM, Rigotti A, Cugno M.

Obstet Gynecol. 2013 Aug;122(2 Pt 2):487-9. doi: 10.1097/AOG.0b013e31828e2612.

PMID:
23884270
14.

Efficacy of eculizumab in a patient with factor-H-associated atypical hemolytic uremic syndrome.

Lapeyraque AL, Frémeaux-Bacchi V, Robitaille P.

Pediatr Nephrol. 2011 Apr;26(4):621-4. doi: 10.1007/s00467-010-1719-3.

PMID:
21161283
15.

[Eculizumab for the treatment of atypical hemolytic uremic syndrome: case report and revision of the literature].

Vaisbich MH, Henriques Ldos S, Watanabe A, Pereira LM, Metran CC, Malheiros DA, Modanez F, Silva JD, Vieira S, Macedo AC, Massarope B, Furusawa EA, Schvartsman BG.

J Bras Nefrol. 2013 Jul-Sep;35(3):237-41. doi: 10.5935/0101-2800.20130037. Review. Portuguese.

16.

Eculizumab therapy in a child with hemolytic uremic syndrome and CFI mutation.

Cayci FS, Cakar N, Hancer VS, Uncu N, Acar B, Gur G.

Pediatr Nephrol. 2012 Dec;27(12):2327-31. doi: 10.1007/s00467-012-2283-9.

PMID:
22903728
17.

Complete remission of thrombotic microangiopathy after treatment with eculizumab in a patient with non-Shiga toxin-associated bacterial enteritis: A case report.

Omura T, Watanabe E, Otsuka Y, Yoshida Y, Kato H, Nangaku M, Miyata T, Oda S.

Medicine (Baltimore). 2016 Jul;95(27):e4104. doi: 10.1097/MD.0000000000004104.

18.

Preservation of renal function in atypical hemolytic uremic syndrome by eculizumab: a case report.

Giordano M, Castellano G, Messina G, Divella C, Bellantuono R, Puteo F, Colella V, Depalo T, Gesualdo L.

Pediatrics. 2012 Nov;130(5):e1385-8. doi: 10.1542/peds.2011-1685.

19.

Eculizumab induces long-term remission in recurrent post-transplant HUS associated with C3 gene mutation.

Al-Akash SI, Almond PS, Savell VH Jr, Gharaybeh SI, Hogue C.

Pediatr Nephrol. 2011 Apr;26(4):613-9. doi: 10.1007/s00467-010-1708-6.

PMID:
21125405
20.

Cryptic activity of atypical hemolytic uremic syndrome and eculizumab treatment.

Belingheri M, Possenti I, Tel F, Paglialonga F, Testa S, Salardi S, Ardissino G.

Pediatrics. 2014 Jun;133(6):e1769-71. doi: 10.1542/peds.2013-2921.

Items per page

Supplemental Content

Support Center